Filing Flows › Pelthos Therapeutics (PTHS) › Q2 2026 › vs Q1 2026
Pelthos Therapeutics (PTHS) Q2 2026 vs Q1 2026 (quarter over quarter)
Pelthos Therapeutics's revenue rose $4.7M (+43%) from $10.9M in Q1 2026 to $15.6M in Q2 2026.
Pelthos Therapeutics, Q2 2026: revenue $15.6M, operating margin -111.0%, net loss $23.4M, operating cash flow −$7.7M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $15.6M | $10.9M | $4.7M | +43% |
| Net loss | $23.4M | $25.1M | −$1.7M | -7% |
| Costs & expenses | $39.0M | $36.0M | $3.0M | +8% |
| Operating costs | $32.9M | $24.0M | $8.9M | +37% |
| Interest & other, net | $6.1M | $12.0M | −$5.9M | -49% |
| Cost of revenue | $3.6M | $1.7M | $1.9M | +116% |
| Research & development | $600K | $186K | $414K | +223% |
| SG&A | $27.7M | $21.1M | $6.6M | +31% |
| Other operating costs | $1.0M | $1.0M | $12K | +1% |
| Operating cash sources | $23.4M | $25.1M | −$1.7M | -7% |
| Depreciation & amortization | $1.3M | $1.5M | −$179K | -12% |
| Share-based compensation | $2.8M | $1.9M | $852K | +45% |
| Working capital & other | $11.7M | $8.5M | $3.1M | +37% |
| Cash used in operations | $7.7M | $13.1M | −$5.5M | -42% |
| Net loss absorbed | $23.4M | $25.1M | −$1.7M | -7% |
Questions
How much did Pelthos Therapeutics's revenue grow quarter over quarter in Q2 2026?
Pelthos Therapeutics's revenue rose $4.7M (+43%) from $10.9M in Q1 2026 to $15.6M in Q2 2026.